BioSenic is an innovative company with the objective of addressing important unmet medical needs in innate immunity, inflammation and organ/function repair.
Mont-St-Guibert, Belgium
Joined September 2012
- Tweets821
- Following390
- Followers1.3K
- Likes214
New post-hoc analysis of our phase 2 clinical trial data suggests a repeated administration cycle for our upcoming phase 3 trial of oral arsenic trioxide (ATO) in chronic graft-versus-host disease (cGvHD).
Read more 👉 lnkd.in/e7zaFr7K
#arsenic #autoimmunity #gvhd
BioSenic SA retweeted
Press Release: @BioSenicSA publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis. To read more, visit: biosenic.com/sites/default/f…
#arsenictrioxide #systemicsclerosis
We will host our Annual General Meeting on June 14 2023.
Preliminary documents for the Annual General Meeting have been made available on our website : lnkd.in/eyW8b7dW
#medialresearch #scientificresearch #health #biotech #pharma #biopharma
We are pleased to anounce that we reacquired global IP rights and to provide update on JTA-004 development.
👉 lnkd.in/eRw97smw
#viscosupplement #rheumatology #scientificresearch #osteoarthritis #paintreatment #health #biotech #clinicaltrial #biotech
We identified biomarkers for #cGvHD and submitted a #patent to EPO to cover a method to evaluate the potency of medications and allow the development of an industrial biomarker analysis kit which could generate a #turnover of 30 to 40 M euros globally. lnkd.in/eFr4FEd8
Last week, we announced 2022 full year results for 2022.
: lnkd.in/gBA26uFM
La semaine dernière nous avons présenté nos résultats pour l'année 2022.
: lnkd.in/gkjFaVSb
#finance #Biotech #health #innovation #immunity #celltherapy #ato
We now have an optimal combination of arsenic and copper to prevent autoimmunity in a murine model of systemic sclerosis.
frontiersin.org/articles/10.…
#biosenic #SSc #arsenic #copper #cuivre #ROS #autoimmunity #immunity
🌍 Today we would like to highlight the importance of #biotechnology research in improving #health for all. We also salute the efforts of #healthcare professionals who work tirelessly to improve the quality of life for #patients.
#WorldHealthDay #Research #AutoimmuneDiseases
We are pleased to welcome Lieven Huysse, MD as Chief Medical Officer.
lnkd.in/eAC6t-Pj
#CMO #medialresearch #scientificresearch #health #biotech #clinicaltrial #pharma #biopharma
BioSenic publishes new data on the mechanism of action of arsenic trioxide
lnkd.in/g3vBAx4b
#arsenic #copper #systemicsclerosis #scientificresearch #health #biotech #research #autoimmunity #immunity
A Fenton-like cation can improve #arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice
👉ATO-Cu benefit to treat pathologies where activated cells are sensitive to oxidative stress.
pubmed.ncbi.nlm.nih.gov/3601…
#GvHD #copper #ROS #autoimmunity
Following the announcement of a new post-hoc analysis of our Phase III JTA-004 trial, boursier .com writes about us!
More about it (in French) : boursier.com/actions/actuali…
A new post-hoc analysis of our Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient open up further potential clinical development options for our viscosupplement.
lnkd.in/ewPkAwnQ
#osteoarthritis #paintreatment
Two weeks ago, we announced a statistical analysis optimization for our ALLOB Phase IIb study for high-risk tibial fractures. Fewer patients needed, significant time and costs reduction, analysis expected Q2 2023.
lnkd.in/eTwWymMy
#biosenic #celltherapy #health
We are delighted to welcome Dr Carole Nicco as Chief Scientific Officer.
📰 Find our press release here ➡ biosenic.com/news-events
#autoimmunediseases #biotech #innovation #frenchtech
BioSenic SA retweeted
Phase II success for autoimmune disease platform in GVHD
ddw-online.com/phase-ii-succ…
#DrugDiscovery @BioSenicSA
"The promising response rates at six months justifies pursuing a phase III study, with a goal of broadening treatment options and reducing the overall morbidity of chronic GVHD in our transplant recipients." says Pr Corey Cutler
➡️ yhoo.it/3zVZN8H
#gvhd #medtech #biotech
Our autoimmune disease platform based on ATO has completed a successful phase IIb trial targeting #cGVHD with a demonstrated efficacy of more than 75%.✅
Phase III is under preparation with expected accelerated examination by FDA.
bit.ly/3NLntm8
#medtech #biotech